On this page
Emrelis
telisotuzumab vedotin-tllv
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Emrelis
Proper name
telisotuzumab vedotin-tllv
Licence type
351(a)
BLA number
761384
Applicant
AbbVie Inc.
Center
CDER
Presentations
2
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 100MG | For Injection | Intravenous | Single-Dose Vial | Rx | May 14, 2025 |
| 20MG | For Injection | Intravenous | Single-Dose Vial | Rx | May 14, 2025 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |